Andrew Blauvelt, M.D., M.B.A.

Dr. Blauvelt is the Owner of Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of Oregon Medical Research Center (OMRC) from 2013-2022. Dr. Blauvelt's research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 450 papers and spoken across the country and world on these topics. In recent years while at OMRC, he has been the international lead/senior investigator on a number of important clinical trials in atopic dermatitis and other diseases, including CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere, and KNOCKOUT. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. For the past 3 years, he has made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Eli Lilly, Incyte, Janssen, Khanda Therapeutics, Leo, Novartis, Oruka, Pfizer, Re-AIM, Regeneron, Sanofi, Sun Pharma, Takeda, and UCBTopic:psoriasis and atopic dermatitisDate added:03/03/2026Date updated:03/03/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:Almirall, Eli Lilly, Leo, Sanofi, and UCBTopic:psoriasis and atopic dermatitisDate added:03/03/2026Date updated:03/03/2026
-
Attribution:SelfType of financial relationship:Individual stocks and stock optionsIneligible company:Oruka and LipidioTopic:psoriasisDate added:03/03/2026Date updated:03/03/2026

Facebook
X
LinkedIn
Forward